Literature DB >> 26449615

Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.

Tomoharu Miyashita1, Kenji Miki2, Takashi Kamigaki2, Isamu Makino3, Hisatoshi Nakagawara3, Hidehiro Tajima3, Hiroyuki Takamura3, Hirohisa Kitagawa3, Sachio Fushida3, Ali K Ahmed4, Mark D Duncan4, John W Harmon4, Tetsuo Ohta3.   

Abstract

We investigated the effect of gemcitabine (GEM), a key drug for pancreatic cancer treatment, on the expression of cell surface MICA/B in pancreatic cancer cells and resulting cytotoxicity of γδ T cells. We assessed the effect of GEM on the upregulation of cell surface MICA/B expression by flow cytometry, utilizing six pancreatic cancer cell lines. MICA and CD16 expressions from resected pancreatic cancer patient specimens, which received neoadjuvant chemotherapy (NAC) with GEM, were analyzed by immunohistochemistry. GEM could increase MICA/B expression on cell surface in pancreatic cancer cell lines (in 2 of 6 cell lines). This effect was most effectively at concentration not affecting cell growth of GEM (0.001 μM), because MICA/B negative population was appeared at concentration at cytostatic and cytotoxic effect to cell growth (0.1 and 10 μM). The cytotoxic activity of γδ T cells against PANC-1 was detected and functions through interactions between NKG2D and MICA/B. However, the enhancement of NKG2D-dependent cytotoxicity with increased MICA/B expression, by GEM treatment, was not observed. In addition, soluble MIC molecules were released from pancreatic cancer cell lines in culture supernatant with GEM treatment. Immunohistochemical staining demonstrated that MICA expression in tumor cells and CD16 positive cells surrounding tumors were significantly higher in the NAC group compared to that of the control group. There was a significant correlation between NAC and MICA expression, as well as NAC and CD16 positive cell expression. The present results indicate that low-dose GEM-induced MICA/B expression enhances innate immune function rather than cytotoxicity in pancreatic cancer. In addition, our result suggests that the inhibition of cleavage and release of MIC molecules from the tumor surface could potentially improve NKG2D-dependent cytotoxicity.

Entities:  

Keywords:  Chemotherapy; Low-dose gemcitabine; Major histocompatibility complex class 1-related chain A/B; Pancreatic cancer; γδ T cell

Mesh:

Substances:

Year:  2015        PMID: 26449615     DOI: 10.1007/s10238-015-0394-x

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  47 in total

1.  Expansion of human peripheral blood γδ T cells using zoledronate.

Authors:  Makoto Kondo; Takamichi Izumi; Nao Fujieda; Atsushi Kondo; Takeharu Morishita; Hirokazu Matsushita; Kazuhiro Kakimi
Journal:  J Vis Exp       Date:  2011-09-09       Impact factor: 1.355

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

3.  RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

Authors:  Manuel A Friese; Jörg Wischhusen; Wolfgang Wick; Markus Weiler; Günter Eisele; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

4.  Immunotherapy updates in pancreatic cancer: are we there yet?

Authors:  Krishna Soujanya Gunturu; Gabriela R Rossi; Muhammad Wasif Saif
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

Review 5.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

Review 6.  Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?

Authors:  Karin E de Visser
Journal:  Cancer Immunol Immunother       Date:  2008-03-15       Impact factor: 6.968

7.  Metastasis-promoting role of extravasated platelet activation in tumor.

Authors:  Tomoharu Miyashita; Hidehiro Tajima; Isamu Makino; Hisatoshi Nakagawara; Hirohisa Kitagawa; Sachio Fushida; John W Harmon; Tetsuo Ohta
Journal:  J Surg Res       Date:  2014-07-22       Impact factor: 2.192

8.  Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.

Authors:  Bodo Schniewind; Matthias Christgen; Roland Kurdow; Sieglinde Haye; Bernd Kremer; Holger Kalthoff; Hendrik Ungefroren
Journal:  Int J Cancer       Date:  2004-03-20       Impact factor: 7.396

9.  Human ovarian tumor cells escape γδ T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules.

Authors:  Jingwei Lu; Reeva Aggarwal; Suman Kanji; Manjusri Das; Matthew Joseph; Vincent Pompili; Hiranmoy Das
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

10.  Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

Authors:  Matilde Todaro; Serena Meraviglia; Nadia Caccamo; Giorgio Stassi; Francesco Dieli
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

View more
  10 in total

1.  A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.

Authors:  Christof T Kaltenmeier; Laura L Vollmer; Lawrence A Vernetti; Lindsay Caprio; Keanu Davis; Vasiliy N Korotchenko; Billy W Day; Michael Tsang; Keren I Hulkower; Michael T Lotze; Andreas Vogt
Journal:  J Pharmacol Exp Ther       Date:  2017-02-02       Impact factor: 4.030

Review 2.  Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.

Authors:  Hélène Kaplon
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

3.  Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment.

Authors:  Qian Chen; Rui Xia; Weiwei Zheng; Luyao Zhang; Ping Li; Xingwei Sun; Jianming Shi
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

4.  In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells.

Authors:  Andrew M Gravett; Angus G Dalgleish; John Copier
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

5.  Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer.

Authors:  Xin Zhang; Dong Wang; Zhidong Li; Defeng Jiao; Linlin Jin; Jingjing Cong; Xiaohu Zheng; Lijun Xu
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

Review 6.  Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance.

Authors:  Elisa Ferretti; Simona Carlomagno; Silvia Pesce; Letizia Muccio; Valentina Obino; Marco Greppi; Agnese Solari; Chiara Setti; Emanuela Marcenaro; Mariella Della Chiesa; Simona Sivori
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

7.  CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.

Authors:  Jolien M R Van der Meer; Paul K J D de Jonge; Anniek B van der Waart; Alexander C Geerlings; Jurgen P Moonen; Jolanda Brummelman; Janne de Klein; Malou C Vermeulen; Ralph J A Maas; Nicolaas P M Schaap; Janneke S Hoogstad-van Evert; Petronella B Ottevanger; Joop H Jansen; Willemijn Hobo; Harry Dolstra
Journal:  Oncoimmunology       Date:  2021-10-01       Impact factor: 8.110

Review 8.  Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.

Authors:  Huiru Zhang; Longyun Ye; Xianjun Yu; Kaizhou Jin; Weiding Wu
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

9.  Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.

Authors:  Tomoharu Miyashita; Kenji Miki; Takashi Kamigaki; Isamu Makino; Hidehiro Tajima; Shinichi Nakanuma; Hironori Hayashi; Hiroyuki Takamura; Sachio Fushida; Ali K Ahmed; John W Harmon; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

Review 10.  The Immune Microenvironment in Pancreatic Cancer.

Authors:  Magdalena Huber; Corinna U Brehm; Thomas M Gress; Malte Buchholz; Bilal Alashkar Alhamwe; Elke Pogge von Strandmann; Emily P Slater; Jörg W Bartsch; Christian Bauer; Matthias Lauth
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.